Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab™
Excerpt from the Press Release:
BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced that a patient case report on the use of lenzilumab™ in critical COVID-19 was published online at OSF Preprints. The case report, titled “COVID-19 associated chronic ARDS successfully treated with lenzilumab” is available at: https://osf.io/xusr9/.
The published case describes a 77-year-old Caucasian male patient with a past medical history of type II diabetes, coronary artery disease with coronary artery bypass graft, systolic heart failure, severe chronic obstructive pulmonary disease (COPD) with emphysema and obstructive sleep apnea. The patient tested positive for SARS-CoV-2 and was admitted to the ICU in March 2020 for COVID-19 and put on respiratory isolation. The patient was treated with steroids, broad spectrum antibiotics for community acquired pneumonia and bronchodilators for possible COPD exacerbation and hydroxychloroquine with zinc. The patient continued to deteriorate for the next 12 weeks with an increase in oxygen demand from continuous low-flow oxygen to high-flow and eventually intermittent bilevel positive airway pressure (BIPAP) and developed acute respiratory distress syndrome (ARDS) during that time.
Click the button below to continue reading the Press Release:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?